| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28, 2024 | ETST Earth Science Tech, Inc. | Saumat Giorgio R. | CEO | Buy | 15,000 | $0.08 | $1,199.00 | - | - | - | |
| Feb 28, 2024 | HIMS Hims & Hers Health, Inc. | Wells David B51 | Director | Sell | 260,000 | $13.16 | $3,421,210.00 | -64.0% | +43.3% | +210.1% | |
| Feb 28, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Conway Vikki L | See "remarks" | Sell | 1,366 | $13.12 | $17,916.46 | -31.8% | +28.0% | +24.7% | |
| Feb 28, 2024 | PBH Prestige Consumer Healthcare Inc. | Fritz Mary Beth57 | SVP Quality &Regulatory | Sell | 663 | $70.30 | $46,606.50 | -1.4% | -9.2% | +20.3% | |
| Feb 27, 2024 | AKBA Akebia Therapeutics, Inc. | Burke Steven Keith61 | SVP, Chief Medical Officer | Sell | 8,367 | $1.52 | $12,717.84 | -1.2% | -34.8% | +9.8% | |
| Feb 27, 2024 | NBIX Neurocrine Biosciences Inc | Norwalk Leslie V64 | Director | Sell | 8,000 | $135.67 | $1,085,388.00 | -100% | +3.3% | -13.6% | |
| Feb 27, 2024 | HIMS Hims & Hers Health, Inc. | Becklund Irene | Pao | Sell | 2,747 | $12.08 | $33,183.76 | -33.3% | +42.2% | +211.9% | |
| Feb 27, 2024 | AKBA Akebia Therapeutics, Inc. | Dahan Michel59 | SVP, Chief Operating Officer | Sell | 10,744 | $1.52 | $16,330.88 | -1.5% | -34.8% | +9.8% | |
| Feb 27, 2024 | AKBA Akebia Therapeutics, Inc. | Hadas Nicole R.60 | SVP, Chief Legal Officer | Sell | 7,411 | $1.52 | $11,264.72 | -1.1% | -34.8% | +9.8% | |
| Feb 27, 2024 | KNSA Kiniksa Pharmaceuticals International, Plc | Paolini John F.51 | Chief Medical Officer | Sell | 10,156 | $21.03 | $213,580.68 | -18.4% | -8.9% | -5.7% | |
| Feb 27, 2024 | AKBA Akebia Therapeutics, Inc. | Butler John P.61 | CEO And President | Sell | 37,733 | $1.52 | $57,354.16 | -1.8% | -34.8% | +9.8% | |
| Feb 27, 2024 | ALKS Alkermes Plc. | Parisi Samuel Joseph62 | VP, Finance (interim Pao) | Sell | 2,559 | $29.65 | $75,874.35 | -24.9% | -20.0% | +17.2% | |
| Feb 26, 2024 | COLL Collegium Pharmaceutical, Inc | Dreyer Scott54 | EVP &Chief Commercial Officer | Sell | 10,000 | $36.43 | $364,270.33 | -3.5% | -6.0% | -21.2% | |
| Feb 26, 2024 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 5,000 | $30.21 | $151,050.00 | -36.8% | -8.2% | +11.2% | |
| Feb 26, 2024 | PBH Prestige Consumer Healthcare Inc. | Fritz Mary Beth57 | SVP Quality &Regulatory | Sell | 9,700 | $70.43 | $683,206.56 | -13.2% | -9.7% | +24.8% | |
| Feb 23, 2024 | UTHR United Therapeutics Corp | Patusky Christopher50 | Director | Sell | 1,680 | $224.00 | $376,320.00 | -99.8% | +21.8% | +59.1% | |
| Feb 23, 2024 | VTRS Viatris Inc | Cuneo Andrew49 | See Remarks | Sell | 4,000 | $13.50 | $54,000.00 | -10.3% | -22.2% | -16.9% | |
| Feb 23, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Mazzariello Gina53 | Chief Legal Officer | Sell | 2,838 | $18.76 | $53,230.66 | -5.8% | -89.9% | -81.3% | |
| Feb 22, 2024 | ETST Earth Science Tech, Inc. | Saumat Giorgio R. | CEO | Buy | 110,000 | $0.08 | $8,250.00 | - | - | - | |
| Feb 22, 2024 | OGN Organon & Co. | Weaver Kirke | Gen. Counsel &Corp. Secy. | Buy | 2,720 | $18.36 | $49,938.93 | +21.8% | +18.4% | -16.5% | |
| Feb 22, 2024 | DERM Journey Medical Corp | Benesch Joseph | Interim CFO | Sell | 2,450 | $3.75 | $9,187.50 | -3.9% | -5.3% | +38.4% | |
| Feb 22, 2024 | EOLS Evolus, Inc. | Beaver Sandra67 | Chief Financial Officer | Sell | 1,821 | $13.08 | $23,820.87 | -1.1% | -1.7% | +6.3% | |
| Feb 22, 2024 | EOLS Evolus, Inc. | Moatazedi David68 | See Remarks | Sell | 7,706 | $13.08 | $100,803.73 | -1.0% | -1.7% | +6.3% | |
| Feb 22, 2024 | EOLS Evolus, Inc. | Avelar Rui67 | See Remarks | Sell | 1,821 | $13.08 | $23,820.87 | -0.5% | -1.7% | +6.3% | |
| Feb 21, 2024 | INM Inmed Pharmaceuticals Inc. | Hull Andrew | Director | Buy | 37,500 | $0.39 | $14,625.00 | +4,947% | -18.4% | -58.0% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.